Valuation : CSL Limited

Market Cap 60.48B 52.04B 48.83B 44.68B 83.39B 5,717B 84.05B 578B 225B 2,922B 227B 222B 9,410B P/E 2027 *
20.7x
P/E 2028 * 18.8x
Enterprise Value 69.42B 59.72B 56.05B 51.28B 95.71B 6,562B 96.47B 663B 258B 3,353B 261B 255B 10,800B EV / Sales 2027 *
4.41x
EV / Sales 2028 * 4.23x
Free-Float
99.97%
Yield 2027 *
2.37%
Yield 2028 * 2.52%
1 day-0.57%
1 week+1.27%
Current month+1.71%
1 month+35.45%
3 months+88.47%
6 months+22.15%
Current year+1.07%
1 week 170.75
Extreme 170.75
177.39
1 month 128.31
Extreme 128.31
177.39
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Director

152 0.0000%
8/21/26 Exercice

Director

244 0.0001%
8/21/26 Exercice

Director

-183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%+1.27%-17.24%-34.99% 60.48B
-1.00%+4.43%+49.60%+1.42% 84.22B
-1.29%+4.27%+519.00%+32.26% 59.43B
-1.60%-7.34%-5.08%+31.05% 50.31B
-2.27%-0.42%+5.38%+163.83% 48.91B
+0.83%+1.36%+58.53%-15.97% 33.17B
-0.64%+0.20%+47.19%+97.87% 25.95B
-0.19%-4.74%+2.30%+196.81% 22.78B
-0.30%-1.67%+67.30%+112.42% 16.73B
-5.19%-9.15%-20.63%+740.91% 14.52B
Average -0.53%-0.74%+70.64%+132.56% 41.65B
Weighted average by Cap. +0.00%+0.95%+91.32%+68.73%

Financials

2027 *2028 *
Net sales 15.75B 13.55B 12.71B 11.63B 21.71B 1,488B 21.88B 150B 58.57B 761B 59.13B 57.84B 2,450B 16.3B 14.02B 13.16B 12.04B 22.47B 1,540B 22.65B 156B 60.61B 787B 61.19B 59.86B 2,535B
Net income 2.83B 2.44B 2.29B 2.09B 3.91B 268B 3.94B 27.07B 10.54B 137B 10.64B 10.41B 441B 3.16B 2.72B 2.55B 2.34B 4.36B 299B 4.39B 30.2B 11.76B 153B 11.87B 11.62B 492B
Net Debt 8.94B 7.69B 7.21B 6.6B 12.32B 845B 12.42B 85.34B 33.24B 432B 33.55B 32.82B 1,390B 8.47B 7.29B 6.84B 6.26B 11.68B 801B 11.78B 80.94B 31.52B 409B 31.82B 31.13B 1,318B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-04 A$174.50 -0.57% 1,074,568
26-09-03 A$175.50 +0.95% 1,150,239
26-09-02 A$173.85 +0.89% 722,041
26-09-01 A$172.31 +0.43% 1,501,636
26-08-31 A$171.57 -0.44% 1,673,346
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
126.29USD
Average target price
121.00USD
Spread / Average Target
-4.19%

Quarterly revenue - Rate of surprise